Cytochrome 4Z1 expression is associated with poor prognosis in colon cancer patients
OncoTargets and Therapy — Al-Saraireh YM, Alshammari FOFO, Youssef AMM, et al. | November 12, 2021
Because of the relatively poor prognosis of patients diagnosed with colon cancer, new therapies are required. Researchers herein investigated the possible value of CYP4Z1, a tumor-related enzyme expressed in many tumors, as a potential biomarker or target for novel anticancer therapies in patients diagnosed with colon cancer.
A large panel of colon tissue types, including normal, benign, primary and metastatic ones, was examined immunohistochemically for CYP4Z1 overexpression.
Benign, primary and metastatic colon tissues showed a high CYP4Z1 expression while normal tissues had a weak or lack of expression.
High histological grades and late stages of the disease had a significantly high rate of CYP4Z1 expression, where patients with metastasis in the lymph nodes had its expression was more evident.
Overall findings suggest an independent value of CYP4Z1 expression as a prognostic predictor of poor overall survival of colon cancer patients and indicate its relevance as target for novel anticancer therapy development.
Read the full article on OncoTargets and Therapy